← Browse by Condition
Medical Condition
recurrent primary peritoneal clear cell adenocarcinoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 1, Phase 2
NCT05231122 Phase 2
Recruiting
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Enrollment
80 pts
Location
United States
Sponsor
Roswell Park Cancer Institute
NCT05920798 Phase 1, Phase 2
Recruiting
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Enrollment
40 pts
Location
United States
Sponsor
Mayo Clinic